To compare the effects of atorvastatin and rosuvastatin on lipid metabolism, atherosclerosis and vascular endothelial function in patients with coronary heart disease.

From June 2017 to October 2018, 300 patients with coronary heart disease admitted to the Second People's Hospital of Nanyang were divided into atorvastatin group (156 cases) and rosuvastatin group (144 cases) according to the random digital table method.The two groups were given basic treatment, and the atorvastatin group was given atorvastatin calcium tablets, 40 mg/time, once a night, while the rosuvastatin group was given rosuvastatin calcium tablets, 10 mg/time, once a night.All patients were treated continuously for 6 months.The blood lipid index, atherosclerosis degree related index and brachial artery diameter change percentage were measured before and after treatment.

After 6 months of treatment, the total cholesterol [(3.02±0.84)mmol/L], triglyceride [(1.25±0.41)mmol/L] and LDL[(1.70±0.52)mmol/L] in the rosuvastatin group were significantly lower than those in the atorvastatin group [(3.55±0.92)mmol/L, (1.69±0.63)mmol/L, (2.05±0.68)mmol/L], the differences were statistically significant(t=7.681, 5.115, 6.207, all P<0.05). The HDL [(1.72±0.37)mmol/L] in the rosuvastatin group was significantly higher than that of the atorvastatin group [(1.40±0.32)mmol/L], the difference was statistically significant(t=5.308, P<0.05). After 6 months of treatment, the scores of carotid plaque score[(4.08±0.59)points] and coronary stenosis degree score[(23.86±3.29)points] in the rosuvastatin group were significantly lower than those before treatment [(4.60±0.75)points, (33.74±4.07)points] and at the same time in the atorvastatin group [(4.39±0.64)points, (27.90±3.61)points], the differences were statistically significant(t=4.276, 17.504, 4.735, 8.415, all P<0.05). After 6 months of treatment, the change percentages of brachial artery diameter in the atorvastatin group and the rosuvastatin group were (8.23±2.59)%, (8.75±2.71)%, respectively, which were significantly higher than those before treatment[(6.48±1.92)%, (6.51±1.86)%], the differences were statistically significant(t=10.780, 11.534, all P<0.05). The change percentage of brachial artery diameter in the rosuvastatin group was significantly higher than that in the atorvastatin group, the difference was statistically significant (t=5.530, P<0.05).

Rosuvastatin is superior to atorvastatin in reducing blood lipid, improving atherosclerosis and vascular endothelial relaxation function in patients with coronary heart disease, and can be widely used.

Coronary disease; Atorvastatin; Rosuvastatin; Lipid metabolism; Carotid intima-media thickness; Carotid plaque score; Coronary stenosis score; Vascular endothelial function